Objective:

To evaluate the efficacy and safety of a treatment for multiple sclerosis (MS) flares alternative to the conventional method, the intravenous route.

Method:

Observational and retrospective, during the months of July-Novembre 2020, coinciding with the period of mobility limitation in Spain due to SARSCoV-2. The sample included 7 patients. The variables were: sex, age, type of MS, result on the expanded disability scale (EDSS), treatment, symptoms and evolution. The programs used were: patient history, outpatient dispensing and magnetic resonance imaging (MRI).

Results:

The results of 7 patients with a mean age of 44.85±13 years were measured. All with a diagnosis of relapsing remitting MS. The mean EDSS score was 3. The main symptoms referred to were: paresthesia, muscle weakness and urinary incontinence. 85% ofthe patients evolved favorably. Anotheraspect that stands out is the comfort ofthe patient from home instead of goingto the hospital.

Discussion and conclusion:

Oral administration of 1,400 mg prednisone for 5 days is a safe, effective and comfortable alternative as a treatment for acute outbreaks in multiple sclerosis. The objective was to evaluate the efficacy and safety of an alternative treatment for MS flares to the conventional method, the intravenous route.

        · |     · |     · ( pdf )